RYTM Rhythm Pharmaceuticals

Rhythm Pharmaceuticals to Present at Jefferies 2019 Healthcare Conference

Rhythm Pharmaceuticals to Present at Jefferies 2019 Healthcare Conference

BOSTON, May 30, 2019 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare genetic disorders of obesity, today announced that Keith Gottesdiener, M.D., Chief Executive Officer of Rhythm, will present a corporate overview at the Jefferies 2019 Healthcare Conference on Thursday, June 6, 2019 at 4:30 p.m. ET in New York, NY.

A live audio webcast of the presentation will be available under “Events & Presentations” in the Investors & Media section of the Company’s website at . A replay of the webcast will be available on the Rhythm website for 30 days following the presentation.

About Rhythm

Rhythm is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of rare genetic disorders of obesity. Rhythm is currently evaluating the efficacy and safety of setmelanotide, the company’s first-in-class MC4R agonist, in Phase 3 studies in patients with POMC deficiency obesity, LEPR deficiency obesity, BBS, and Alström syndrome. Rhythm is dedicated to improving the understanding of severe obesity that results from specific genetic disorders. For healthcare professionals, visit  for more information. For patients and caregivers, visit  for more information. The company is based in Boston, MA.

Corporate Contact:

David Connolly

Head of Investor Relations and Corporate Communications

Rhythm Pharmaceuticals, Inc.

857-264-4280

Investor Contact:

Hannah Deresiewicz

Stern Investor Relations, Inc.

212-362-1200

Media Contact:

Adam Daley

Berry & Company Public Relations

212-253-8881

EN
30/05/2019

Underlying

RYTMRhythm Pharmaceuticals

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Rhythm Pharmaceuticals

 PRESS RELEASE
Free
RYTM Rhythm Pharmace...

Rhythm Pharmaceuticals Announces Additional Positive Data from Phase 3...

Rhythm Pharmaceuticals Announces Additional Positive Data from Phase 3 TRANSCEND trial of Setmelanotide in Patients with Acquired Hypothalamic Obesity -- -18.8% placebo-adjusted difference in BMI reduction achieved in all patients (N=142) at 52 weeks, including 12 Japanese patients and 10 supplemental patients with acquired hypothalamic obesity -- -- March 20, 2026 PDUFA goal date for sNDA for setmelanotide in acquired hypothalamic obesity -- BOSTON, March 01, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focus...

March 1, 2026 1 EN
 PRESS RELEASE
Free
RYTM Rhythm Pharmace...

Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Finan...

Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update -- Fourth quarter 2025 net product revenue from global sales of IMCIVREE® (setmelanotide) of $57.3 million -- -- March 20, 2026 PDUFA goal date for sNDA for setmelanotide in acquired hypothalamic obesity (HO) ---- Phase 2 open-label extension data showed bivamelagon achieved persistent BMI reductions at six and nine months; Completed positive end-of-Phase-2 meeting with FDA ---- On track to report topline data from 12-patient Japanese cohort of setmelanotide Phase 3 trial in acquired HO ...

February 26, 2026 1 EN
Free Trial
RYTM Rhythm Pharmace...

Rhythm Pharmaceuticals Inc: 1 director

A director at Rhythm Pharmaceuticals Inc sold/sold after exercising options 7,954 shares at 101.293USD and the significance rating of the trade was 63/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's ...

RYTM RHYTHM PHARMACEUTICALS
02/20/26 February 20, 2026 1 EN
 PRESS RELEASE
Free
RYTM Rhythm Pharmace...

Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Fin...

Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026 BOSTON, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 8 a.m. ET on Thursday, February 26, 2026 to report its fourth quarter and full year 2025 financial results and provide a corporate update. To access the live conference call, part...

February 17, 2026 1 EN
 PRESS RELEASE
Free
RYTM Rhythm Pharmace...

Rhythm Pharmaceuticals Announces Participation in Upcoming Guggenheim ...

Rhythm Pharmaceuticals Announces Participation in Upcoming Guggenheim Biotech Summit BOSTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that Hunter C. Smith, Chief Financial Officer, will participate in a fireside chat at the upcoming Guggenheim Emerging Outlook: Biotech Summit 2026 conference on Wednesday, February 11 at 11:00 a.m. ET in New York. The fireside chat will be webcasted and available u...

February 5, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch